new-recommended-broker-banner new-recommended-broker-banner

Supernus Pharmaceuticals (SUPN) Stock Rallies After Beating Q3 Earnings Estimates

Updated: 4 Nov 2020

Shares of pharmaceutical company Supernus Pharmaceuticals (NASDAQ: SUPN) have rallied premarket on Wednesday after the company released its third-quarter earnings results after the close on Tuesday evening. 

Supernus revealed that its Q3 revenue had risen to $155.1 million, compared to $102.1 million in 2019. $152.1 million of its revenue came from product sales while $3 million came from royalties. 

However, it is the company’s earnings and full-year revenue guidance that has caused the rise in its share price.


The Maryland based firm said its earnings per share came in at $0.74, above the $0.54 in Q3 2019 and way over analysts estimates that were in the range of $0.29 to $0.37.  

Supernus increased its full-year product sales guidance to $500-$525 million from the previous $460-$500 million. 

Tuesday’s earnings report has seen Supernus shares surge over 19% to $21.60 after the previous sessions close at $18.16. 


CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .